-
公开(公告)号：KR100970579B1
公开(公告)日：2010-07-16
申请号：KR1020080028713
申请日：2008-03-28
Applicant: 한림대학교 산학협력단
IPC: C07K19/00
Abstract: 본 발명은 피리독살-5'-인산 탈인산화효소와 단백질 수송도메인이 공유결합된 피리독살-5'-인산 탈인산화효소 융합 단백질을 제조함으로써 용이하게 세포 내로 도입 가능한 피리독살-5'-인산 탈인산화효소 융합 단백질에 관한 것으로서, 좀더 자세히는 본 발명의 단백질 수송 도메인은 15∼30개의 아미노산으로 구성되고, 5개 이상의 트립토판을 포함하는 비친수성 도메인(hydrophobic domain), 라이신을 다수 포함하는 친수성 도메인(hydrophilic domain) 및 상기 두 도메인을 분리시켜 주는 스페이서(spacer)로 구성된 단백질 수송 도메인이 피리독살-5'-인산 탈인산화효소의 적어도 일측 말단에 융합되어 있으며, 대조군과 비교할 때 원활히 PC12 신경세포 내로 농도 의존적, 시간 의존적으로 침투하며, 세포 내에서 36시간 이상 지속되었고 세포 내 피리독살-5'-인산의 농도를 현저히 낮추는 효과를 나타내었다.
인간 뇌 피리독살-5'-인산 탈인산화효소(PLPP), PEP-1 펩타이드, 단백질 세포도입, 단백질 치료, 피리독살-5'-인산(PLP)-
公开(公告)号：KR1020090113462A
公开(公告)日：2009-11-02
申请号：KR1020080039197
申请日：2008-04-28
Applicant: 한림대학교 산학협력단 , 주식회사 라이프투게더
IPC: A61K33/14 , A61K36/899 , A61K36/48 , A61P17/00
Abstract: PURPOSE: A natural composition suppressing skin inflammation including atopic dermatitis is provided to reduce mRNA expression of various cytokines. CONSTITUTION: A natural composition for preventing and treating skin inflammation contains mixture of salt, Phyllostachys nigra extract and Aspalathus linearis extract in weight ratio of 1: 0.001-10:0.001-10 as an active ingredient. A cosmetic composition is used in the formulation of essence or skin. The extract is obtained using 50-90% of ethanol or hot water.
Abstract translation: 目的：提供抑制皮肤炎症（包括特应性皮炎）的天然组合物，以减少各种细胞因子的mRNA表达。 构成：用于预防和治疗皮肤炎症的天然组合物含有重量比为1:0.001-10:0.001-10的盐，黑曲霉提取物和芦荟提取物的混合物作为活性成分。 化妆品组合物用于精华或皮肤制剂中。 使用50-90％的乙醇或热水获得提取物。
-
公开(公告)号：KR1020090111894A
公开(公告)日：2009-10-28
申请号：KR1020080037494
申请日：2008-04-23
Applicant: 한림대학교 산학협력단
IPC: C07K19/00
CPC classification number: C12N9/1223 , A61K38/45 , A61K47/64 , C07K2319/01 , C12Y207/03002
Abstract: PURPOSE: A cell permeable creatine kinase fusion protein is provided to effectively treat epilepsy, Alzheimer disease, Parkinson disease and heart disease. CONSTITUTION: A cell permeable creatine kinase fusion protein is bound with a transport domain at the end of one side of creatine kinase by covalent bond. The transport domain comprises 9 to 15 of amino acid residues. The transport domain contains 3/4 or more of arginine or lysine residue. The transport domain is HIV Tat 49-57 residue, oligolysine, oligoarginine or oligo. The fusion protein has an amino acid of the sequence number 7.
Abstract translation: 目的：提供细胞渗透性肌酸激酶融合蛋白，有效治疗癫痫，阿尔茨海默病，帕金森病和心脏病。 构成：细胞渗透性肌酸激酶融合蛋白通过共价键与肌酸激酶一侧末端的转运结构域结合。 转运结构域包含9-15个氨基酸残基。 转运结构域含有3/4以上的精氨酸或赖氨酸残基。 运输区域是HIV Tat 49-57残基，寡聚赖氨酸，寡精氨酸或寡核苷酸。 融合蛋白具有序列号7的氨基酸。
-
54.发明公开세포투과성 융합단백질 세포도입 활성 증가용3-Ｏ-[β-Ｄ-글루코피라노실(1→4)-α-Ｌ-아라비노피라노실]-헤데라제닌 无效3-O- [β-D-GLUCOPYRANOSYL（1-> 4）-alpha-L-阿拉伯糖苷] -HEDERAGENIN增加细胞转导融合蛋白的转录活性
公开(公告)号：KR1020090026838A
公开(公告)日：2009-03-16
申请号：KR1020070091867
申请日：2007-09-11
Applicant: 한림대학교 산학협력단 , 재단법인춘천바이오산업진흥원
IPC: A61K31/7048 , A61K31/702
CPC classification number: A61K31/704 , A61K36/25
Abstract: A 3-O-(beta-D-glucopyranosyl(1->4)-alpha-L-arabinopyranosyl)-hederagenin is provided to be applied to aiding agent, medicine, cosmetic material increasing infiltration efficiency of the cell permeability fusion protein including Tat-SOD etc. and various disease treating field. A 3-O-(beta-D-glucopyranosyl(1->4)-alpha-L-arabinopyranosyl)-hederagenin improves cell permeation rate of cell permeability fusion protein. The cell permeability fusion protein is formed by covalent bonding HIV-Tat(49-57) consisting of 6~15 amino acids, oligolysine, oligoarginine, oligo(lysine and arginine), protein transport domain selected from PEP-1 and cell non-porous protein. The cell permeability fusion protein is HIV-Tat-Cu,Zn superoxide dismutase. The 3-O- (beta-D-glucopyranosyl(1->4)-alpha-L-arabinopyranosyl)-hederagenin is separated from Fatsia japonica.
Abstract translation: 提供3-O-（β-D-吡喃葡萄糖基（1→4）-alpha-L-阿拉伯吡喃糖基）-hederagenin应用于助剂，药物，化妆品，增加细胞渗透性融合蛋白（包括Tat）的渗透效率 -SOD等和各种疾病治疗领域。 3-O-（β-D-吡喃葡萄糖基（1-> 4）-alpha-L-阿拉伯吡喃糖基）-hederagenin提高细胞渗透性融合蛋白的细胞渗透速率。 细胞渗透性融合蛋白是通过共价键合形成的HIV-Tat（49-57）由6〜15个氨基酸，寡聚赖氨酸，寡精氨酸，寡核苷酸（赖氨酸和精氨酸）组成，蛋白质转运结构域选自PEP-1和细胞无孔 蛋白。 细胞渗透性融合蛋白是HIV-Tat-Cu，Zn超氧化物歧化酶。 从Fatsia japonica分离出3-O-（β-D-吡喃葡萄糖基（1-> 4）-alpha-L-阿拉伯吡喃糖基） - 原基因。
-
公开(公告)号：KR1020090026382A
公开(公告)日：2009-03-13
申请号：KR1020070091301
申请日：2007-09-10
Applicant: 한림대학교 산학협력단
IPC: C07K19/00
Abstract: A cell introduction PTEN fusion protein is provided to improve cell permeation of PTEN(Phosphatase and tensin homologue deleted on chromosome 10) and to treat cancer, death of skin cell and atopy. A cell introduction PTEN fusion protein has amino acid sequences of a sequence number 7, a sequence number 9 or a sequence number 11 and is formed by covalent bonding PEP-1 protein transport domain of a sequence number 3 at one-side end of PTEN(Phosphatase and tensin homologue deleted on chromosome 10) protein. The recombinant polynucleotide has nucleotide sequence of a sequence number 6, a sequence number 8 or a sequence number 10. The cell introduction PTEN fusion protein is coded from the recombinant polynucleotide.
Abstract translation: 提供细胞介导PTEN融合蛋白，以改善PTEN（10号染色体上缺失的磷酸酶和张力蛋白同源物）的细胞渗透，并治疗癌症，皮肤细胞死亡和特应性。 细胞介导PTEN融合蛋白具有序列号7，序列号9或序列号11的氨基酸序列，并且通过在PTEN的一侧共价键合3号序列的PEP-1蛋白转运结构域（ 磷酸酶和张力蛋白同源物在染色体10）上缺失。 重组多核苷酸具有序列号6，序列号8或序列号10的核苷酸序列。细胞介导PTEN融合蛋白从重组多核苷酸编码。
-
Patent Agency Ranking
公开(公告)号：KR100857691B1
公开(公告)日：2008-09-23
申请号：KR1020070053211
申请日：2007-05-31
Applicant: 한림대학교 산학협력단 , 재단법인춘천바이오산업진흥원 , 서림바이오 주식회사
IPC: A61K36/533 , A61P3/10
CPC classification number: A61K36/53 , A23V2200/328 , A61K2236/33 , A61K2236/35 , Y10S514/866
Abstract: A composition comprising an extract of Elsholtzia ciliata is provided to show excellent anti-oxidative activity, advanced glycation end product inhibitory activity and aldose reductase inhibitory action, thereby being used for preventing or treating diabetic complications. A composition for inhibiting diabetic complications comprises an extract of Elsholtzia ciliata, wherein the extract is obtained by using an organic solvent such as C1-5 alcohol, ethylacetate, hexane, acetone, chloroform, and methylene chloride. A food or a medicine for inhibiting the diabetic complications comprises the composition.
Abstract translation: 提供了包含Elsholtzia ciliata提取物的组合物以显示优异的抗氧化活性，晚期糖基化终产物抑制活性和醛糖还原酶抑制作用，从而用于预防或治疗糖尿病并发症。 用于抑制糖尿病并发症的组合物包括Elsholtzia ciliata的提取物，其中通过使用有机溶剂如C 1-5醇，乙酸乙酯，己烷，丙酮，氯仿和二氯甲烷获得提取物。 用于抑制糖尿病并发症的食品或药物包含该组合物。
-
-
公开(公告)号：KR101761550B1
公开(公告)日：2017-07-27
申请号：KR1020160060729
申请日：2016-05-18
Applicant: 한림대학교 산학협력단
IPC: A61K38/16 , A61K9/20 , A61K9/48 , A61K9/00 , C07K14/47 , C07K14/005 , C07K14/395
CPC classification number: A61K38/16 , A61K9/0019 , A61K9/20 , A61K9/48 , C07K14/005 , C07K14/395 , C07K14/47 , C07K2319/00
Abstract: 과제: 세포침투가용이하고, 염증성관절염에효과적인약학조성물을제공하려는것. 해결수단: 본발명은연골조직내로투과가능한 PEA15 융합단백질을유효성분으로함유하는관절염예방및 치료용약제학적조성물에관한것으로, 염증유발연골세포내에서염증마커의단백질및 mRNA 발현수준및 염증성싸이토카인의발현을저하시켰다. 따라서, 본발명에따른 PEP-1-PEA15 융합단백질은염증성관절염의예방또는치료용약학조성물로서유용할것으로예상된다.
Abstract translation: 问题：提供易于穿透细胞并对炎性关节炎有效的药物组合物。 解决问题的手段：关节炎预防的本发明和涉及蛋白和mRNA和炎性细胞因子的表达在含有可渗透PEA15融合蛋白进入软骨组织作为活性成分的炎性软骨细胞中的炎症标记物的水平的治疗性药物组合物 Lt。 因此，预期本发明的PEP-1-PEA15融合蛋白可用作用于预防或治疗炎性关节炎的药物组合物。
-
公开(公告)号：KR1020170033557A
公开(公告)日：2017-03-27
申请号：KR1020150131419
申请日：2015-09-17
Applicant: 한림대학교 산학협력단
Abstract: 파킨슨병은뇌의흑색질내에서도파민뉴런이점차상실되는신경퇴행성질환이다. 본발명자들은 PIM2 융합단백질이 SH-SY5Y 신경아세포종세포및 파킨슨병동물모델에서산화스트레스로부터도파민뉴런을보호할수 있음을밝혀내었다. PIM2 융합단백질은 SH-SY5Y 세포내로그리고뇌의흑색질내로잘 이동함을웨스턴블랏분석으로확인하였다. PIM2 융합단백질은 MPP로유도되는활성산소종생성및 DNA 단편화를현저히저해하였으며, 결과적으로 SH-SY5Y 세포의생존을유도했다. 나아가, TH 항체및 크레실바이올렛염색을이용한면역조직화학분석데이타는 PIM2 융합단백질이 MPTP와같은산화스트레스에대하여흑색질내의도파민세포를현저히보호함을나타낸다. 따라서, PIM2 융합단백질은파킨슨병의예방및 치료용도로이용가능하다.
Abstract translation: 帕金森病是一种神经退行性疾病，其中多巴胺能神经元在脑黑质中逐渐消失。 本发明人已经发现，可以在保护PIM2多巴胺神经元免受氧化应激帕金森氏病，所述融合蛋白的SH-SY5Y成神经细胞瘤细胞和动物模型。 通过蛋白质印迹分析证实PIM2融合蛋白迁移到SH-SY5Y细胞中并进入脑的黑质。 PIM2融合蛋白显着抑制MPP诱导的活性氧的产生和DNA片段化，导致SH-SY5Y细胞存活。 此外，使用数据TH抗体和甲酚紫染色的免疫组织化学分析表明，显著保护对抗氧化应激，黑质多巴胺能细胞，例如作为融合蛋白PIM2 MPTP。 因此，PIM2融合蛋白可用于预防和治疗帕金森病。
-
-
-
-
-
-
-
-
-
Search Results
106
records
(took 0.03 seconds)
